Edgewise Therapeutics, Inc. (EWTX) company profile
Close on Nov 17, 2026Market cap $4.57BP/E –Yield –
About Edgewise Therapeutics
Pharmaceutical Preparations, SIC 2834
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision small molecule medicines for severe neuromuscular and cardiac disorders. The company utilizes a proprietary, muscle-focused drug discovery platform that evaluates integrated muscle function in whole organ extracts. Its pipeline features lead candidate sevasemten, an orally administered fast myofiber myosin inhibitor in late-stage clinical trials for Becker muscular dystrophy and Duchenne muscular dystrophy. Edgewise is also developing cardiac sarcomere modulators, including clinical-stage candidate EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure with preserved ejection fraction, along with preclinical cardiometabolic programs. Its intended customer base comprises patients affected by rare, debilitating skeletal and cardiac muscle conditions with limited or no approved therapies.
The company retains global development and commercialization rights to all its programs and plans to establish an internal commercial organization within the United States while evaluating collaborations globally. The provided excerpt contains no information regarding the company's founding year, website, or headquarters location.
Summary of the business section of Edgewise Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Edgewise Therapeutics, Inc.
- Headquarters
- Boulder, CO
- Address
- 1715 38th St 80301
- Phone
- (720) 262-7002
- Website
- edgewisetx.com
- Employees
- 146, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Denver, Colorado
Stock & identifiers
- Ticker
- EWTX
- Exchange
- Nasdaq
- IPO date
- Mar 26, 2021
- Shares outstanding
- 109M, Jul 31, 2026
- Public float
- $1.20B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1710072
- CUSIP
- 28036F105
- ISIN
- US28036F1057
- FIGI
- BBG00K4Y2H24
- Share class FIGI
- BBG00K4Y2H33
- EIN
- 82-1725586
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Alan J. Russell | Chief Scientific Officer, Director | 31,856 |
| Kevin Koch | President and CEO, Director | 391,272 |
| Michael Nofi | Chief Financial Officer | 6,495 |
| Behrad Derakhshan | Chief Business Officer | 29,426 |
| John R. Moore | General Counsel | 15,995 |
| Joanne M. Donovan | CMO | 8,625 |
| Robert Blaustein | Chief Development Officer | – |
| R. Michael Carruthers | Chief Financial Officer | 86,162 |
| Marc Semigran | Chief Development Officer | 6,716 |
| Jonathan C. Fox | Director | 25,141 |
| Jonathan D. Root | Director | 15,625 |
| Laura Brege | Director | – |
| Peter A. Thompson | Director | 443,792 |
| Arlene Morris | Director | – |
| Christopher Nathan Martin | Director | – |
| Badreddin Edris | Director | 96,760 |
| Genesis GP LLC OrbiMed | Director | 14,809,075 |
| Advisors Llc Orbimed | Director | 319,599 |
| Capital GP VI LLC OrbiMed | Director | 14,436,497 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.36M | $7.87M | $3.32M | $286 | $139 |
| FY2024 | $7.60M | $35.60M | $2.91M | $307 | $104 |
| FY2023 | $3.98M | $9.61M | $1.74M | $128 | $105 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Kevin Koch, Ph.D. President and Chief Executive Officer | $670.00K | $1.17M | $5.04M | $462.30K | $14.00K | $7.36M | -3% |
| Michael P. Nofi Chief Financial Officer | $67.81K | $799.75K | $3.39M | $29.89K | – | $4.28M | – |
| Robert Blaustein, M.D., Ph.D. Former Chief Development Officer | $525.00K | $999.48K | $2.80M | $227.61K | $14.00K | $4.57M | – |
| R. Michael Carruthers Former Chief Financial Officer | $465.69K | $392.71K | $1.50M | $214.22K | $14.00K | $2.59M | – |
| Behrad Derakhshan, Ph.D. Chief Operating Officer | $520.00K | $401.70K | $1.73M | $269.10K | $14.00K | $2.93M | +1% |
| Joanne M. Donovan, M.D., Ph.D. Chief Medical Officer | $530.36K | $376.59K | $1.62M | $243.97K | $14.00K | $2.79M | -5% |
| Alan Russell, Ph.D. Co-Founder and Chief Scientific Officer | $499.58K | $376.59K | $1.62M | $229.81K | $8.48K | $2.73M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 26, 2021
- Offer price
- $16.00
- Securities offered
- 11,000,000
- Gross proceeds
- $176.00M
- Exchange
- Nasdaq
- First trading day
- Mar 26, 2021
- First-day close
- $30.00+87.5%
- Lock-up ends (est.)
- Sep 22, 2021
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 146 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 13, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 14, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 22, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 26, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 17, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?